Post-transplant liver biopsy and the immune response: lessons for the clinician

References

• Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6(8), 1774–1780 (2006).
   PubMed Web of Science ®Google Scholar
• Li F, Atz ME, Reed EF. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr. Opin. Immunol. 21(5), 557–562 (2009).
   PubMed Web of Science ®Google Scholar
• O’Leary JG, Kaneku H, Susskind BM et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am. J. Transplant. 11(9), 1868–1876 (2011).
   PubMed Web of Science ®Google Scholar
• Knechtle SJ. Seek and you will find: antibody and the liver. Am. J. Transplant. 11(3), 424–425 (2011).
   PubMedGoogle Scholar
• Musat AI, Agni RM, Wai PY et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am. J. Transplant. 11(3), 500–510 (2011).
   PubMedGoogle Scholar
• Donaldson PT, Alexander GJ, O’Grady J et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1(8539), 945–951 (1987).
   PubMed Web of Science ®Google Scholar
• Stefanova I, Dorfman JR, Tsukamoto M, Germain RN. On the role of self-recognition in T-cell responses to foreign antigen. Immunol. Rev. 191, 97–106 (2003).
   PubMed Web of Science ®Google Scholar
• Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 69(6), 545–556 (2007).
   PubMedGoogle Scholar
• Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr. Opin. Organ Transplant. 13(4), 438–444 (2008).
   PubMed Web of Science ®Google Scholar
• Kroemer A, Edtinger K, Li XC. The innate natural killer cells in transplant rejection and tolerance induction. Curr. Opin. Organ Transplant. 13(4), 339–343 (2008).
   PubMed Web of Science ®Google Scholar
• Hanvesakul R, Spencer N, Cook M et al. Donor HLA-C genotype has a profound impact on the clinical outcome following liver transplantation. Am. J. Transplant. 8(9), 1931–1941 (2008).
   PubMed Web of Science ®Google Scholar
• Chen Y, Wood KJ. Interleukin-23 and TH17 cells in transplantation immunity: does 23+17 equal rejection? Transplantation 84(9), 1071–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Chen L, Ahmed E, Wang T et al. TLR signals promote IL-6/IL-17-dependent transplant rejection. J. Immunol. 182(10), 6217–6225 (2009).
   PubMed Web of Science ®Google Scholar
• Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5(11), 1303–1307 (1999).
   PubMed Web of Science ®Google Scholar
• Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5(11), 1298–1302 (1999).
   PubMed Web of Science ®Google Scholar
• Fan Z, Spencer JA, Lu Y et al. In vivo tracking of ‘color-coded’ effector, natural and induced regulatory T cells in the allograft response. Nat. Med. 16(6), 718–722 (2010).
   PubMed Web of Science ®Google Scholar
• Billerbeck E, Bottler T, Thimme R. Regulatory T cells in viral hepatitis. World J. Gastroenterol. 13(36), 4858–4864 (2007).
   PubMed Web of Science ®Google Scholar
• Carpentier A, Conti F, Stenard F et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am. J. Transplant. 9(9), 2102–2112 (2009).
   PubMed Web of Science ®Google Scholar
• Ando K, Guidotti LG, Cerny A, Ishikawa T, Chisari FV. CTL access to tissue antigen is restricted in vivo. J. Immunol. 153(2), 482–488 (1994).
   PubMed Web of Science ®Google Scholar
• Klein I, Crispe IN. Complete differentiation of CD8+ T cells activated locally within the transplanted liver. J. Exp. Med. 203(2), 437–447 (2006).
   PubMed Web of Science ®Google Scholar
• Kern M, Popov A, Kurts C, Schultze JL, Knolle PA. Taking off the brakes: T-cell immunity in the liver. Trends Immunol. 31(8), 311–317 (2010).
   PubMed Web of Science ®Google Scholar
• Crispe IN. The liver as a lymphoid organ. Annu. Rev. Immunol. 27, 147–163 (2009).
   PubMed Web of Science ®Google Scholar
• Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3(1), 51–62 (2003).
   PubMed Web of Science ®Google Scholar
• Benseler V, Tay SS, Bowen DG, Bertolino P. Role of the hepatic parenchyma in liver transplant tolerance: a paradigm revisited. Dig. Dis. 29(4), 391–401 (2011).
   PubMed Web of Science ®Google Scholar
• von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343(14), 1020–1034 (2000).
   PubMed Web of Science ®Google Scholar
• Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343(8901), 831–836 (1994).
   PubMed Web of Science ®Google Scholar
• Cines DB, Pollak ES, Buck CA et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91(10), 3527–3561 (1998).
   PubMed Web of Science ®Google Scholar
• Aird WC. Phenotypic heterogeneity of the endothelium: I. structure, function, and mechanisms. Circ. Res. 100(2), 158–173 (2007).
   PubMed Web of Science ®Google Scholar
• Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7(9), 678–689 (2007).
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57, 827–872 (1995).
   PubMed Web of Science ®Google Scholar
• Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 9(10), 866–873 (1995).
   PubMed Web of Science ®Google Scholar
• Alon R, Kassner PD, Carr MW, Finger EB, Hemler ME, Springer TA. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J. Cell Biol. 128(6), 1243–1253 (1995).
   PubMed Web of Science ®Google Scholar
• Berlin C, Bargatze RF, Campbell JJ et al. α 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 80(3), 413–422 (1995).
   PubMed Web of Science ®Google Scholar
• Lalor PF, Clements JM, Pigott R, Humphries MJ, Spragg JH, Nash GB. Association between receptor density, cellular activation, and transformation of adhesive behavior of flowing lymphocytes binding to VCAM-1. Eur. J. Immunol. 27(6), 1422–1426 (1997).
   PubMed Web of Science ®Google Scholar
• Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 349(9050), 490–495 (1997).
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Qin S, Bacon KB, Mackay CR, Butcher EC. Biology of chemokine and classical chemoattractant receptors: differential requirements for adhesion-triggering versus chemotactic responses in lymphoid cells. J. Cell Biol. 134(1), 255–266 (1996).
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Bowman EP, Murphy K et al. 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7. J. Cell Biol. 141(4), 1053–1059 (1998).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 β. Nature 361(6407), 79–82 (1993).
   PubMed Web of Science ®Google Scholar
• Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4(6), 432–444 (2004).
   PubMed Web of Science ®Google Scholar
• Wong J, Johnston B, Lee SS et al. A minimal role for selectins in the recruitment of leukocytes into the inflamed liver microvasculature. J. Clin. Invest. 99(11), 2782–2790 (1997).
   PubMed Web of Science ®Google Scholar
• Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp. Hepatol. 1(1), 1 (2002).
   PubMedGoogle Scholar
• Adams DH, Hubscher SG, Fisher NC, Williams A, Robinson M. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 24(3), 533–538 (1996).
   PubMed Web of Science ®Google Scholar
• Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J. Immunol. 169(2), 983–992 (2002).
   PubMed Web of Science ®Google Scholar
• Edwards S, Lalor PF, Nash GB, Rainger GE, Adams DH. Lymphocyte traffic through sinusoidal endothelial cells is regulated by hepatocytes. Hepatology 41(3), 451–459 (2005).
   PubMed Web of Science ®Google Scholar
• McDonald B, McAvoy EF, Lam F et al. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. J. Exp. Med. 205(4), 915–927 (2008).
   PubMed Web of Science ®Google Scholar
• Bonder CS, Norman MU, Swain MG et al. Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: a role for α-4 integrin and vascular adhesion protein-1. Immunity 23(2), 153–163 (2005).
   PubMed Web of Science ®Google Scholar
• Shetty S, Weston CJ, Oo YH et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J. Immunol. 186(7), 4147–4155 (2011).
   PubMed Web of Science ®Google Scholar
• Briscoe DM, Alexander SI, Lichtman AH. Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr. Opin. Immunol. 10(5), 525–531 (1998).
   PubMed Web of Science ®Google Scholar
• Tullius SG, Heemann UW, Zeilinger K et al. Binding of lymphocytes to acutely rejecting rat kidney allografts in vitro is guided by events in the graft itself rather than by sensitization of host lymphocytes. Transpl. Immunol. 3(2), 91–97 (1995).
   PubMedGoogle Scholar
• Turunen JP, Mattila P, Halttunen J, Häyry P, Renkonen R. Evidence that lymphocyte traffic into rejecting cardiac allografts is CD11a- and CD49d-dependent. Transplantation 54(6), 1053–1058 (1992).
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Fu XM, Issekutz T, Cohen Z. Differential regulation of rejection of small intestinal and skin allografts in rats by injection of antibodies to ICAM-1 or the integrins α 4, α L, or β 2. Cell. Immunol. 184(1), 74–82 (1998).
   PubMed Web of Science ®Google Scholar
• Martelius T, Salmi M, Wu H et al. Induction of vascular adhesion protein-1 during liver allograft rejection and concomitant cytomegalovirus infection in rats. Am. J. Pathol. 157(4), 1229–1237 (2000).
   PubMed Web of Science ®Google Scholar
• Martelius T, Salaspuro V, Salmi M et al. Blockade of vascular adhesion protein-1 inhibits lymphocyte infiltration in rat liver allograft rejection. Am. J. Pathol. 165(6), 1993–2001 (2004).
   PubMed Web of Science ®Google Scholar
• Fujisaki S, Miyake H, Amano S, Nakayama H, Oida T, Takizawa H. Expression of CD44 in rat liver allografts during rejection. J. Hepatobiliary. Pancreat. Surg. 5(2), 196–199 (1998).
   PubMedGoogle Scholar
• Shields PL, Morland CM, Salmon M, Qin S, Hubscher SG, Adams DH. Chemokine and chemokine receptor interactions provide a mechanism for selective T-cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163(11), 6236–6243 (1999).
   PubMed Web of Science ®Google Scholar
• Harvey CE, Post JJ, Palladinetti P et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 74(3), 360–369 (2003).
   PubMed Web of Science ®Google Scholar
• Goddard S, Williams A, Morland C et al. Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. Transplantation 72(12), 1957–1967 (2001).
   PubMed Web of Science ®Google Scholar
• Grant AJ, Goddard S, Ahmed-Choudhury J et al. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am. J. Pathol. 160(4), 1445–1455 (2002).
   PubMed Web of Science ®Google Scholar
• Eksteen B, Miles A, Curbishley SM et al. Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J. Immunol. 177(1), 593–603 (2006).
   PubMed Web of Science ®Google Scholar
• Oo YH, Weston CJ, Lalor PF et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J. Immunol. 184(6), 2886–2898 (2010).
   PubMed Web of Science ®Google Scholar
• Adams DH, Hubscher S, Fear J, Johnston J, Shaw S, Afford S. Hepatic expression of macrophage inflammatory protein-1 α and macrophage inflammatory protein-1 β after liver transplantation. Transplantation 61(5), 817–825 (1996).
   PubMed Web of Science ®Google Scholar
• International Working Party. Terminology for hepatic allograft rejection. Hepatology 22(2), 648–654 (1995).
   PubMed Web of Science ®Google Scholar
• Shaked A, Ghobrial RM, Merion RM et al.; A2ALL Study Group. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am. J. Transplant. 9(2), 301–308 (2009).
   PubMedGoogle Scholar
• Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 25(3), 658–663 (1997).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Adeyi O, Bellamy CO et al.; Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 44(2), 489–501 (2006).
   PubMed Web of Science ®Google Scholar
• Schlitt HJ, Nashan B, Krick P et al. Intragraft immune events after human liver transplantation. Correlation with clinical signs of acute rejection and influence of immunosuppression. Transplantation 54(2), 273–278 (1992).
   PubMed Web of Science ®Google Scholar
• Dousset B, Hubscher SG, Padbury RT et al. Acute liver allograft rejection – is treatment always necessary? Transplantation 55(3), 529–534 (1993).
   PubMed Web of Science ®Google Scholar
• Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 57(6), 857–859 (1994).
   PubMed Web of Science ®Google Scholar
• Rush D, Jeffery J, Trpkov K, Solez K, Gough J. Effect of subclinical rejection on renal allograft histology and function at 6 months. Transplant. Proc. 28(1), 494–495 (1996).
   PubMed Web of Science ®Google Scholar
• Farges O, Nocci KA, Sebagh M, Reynes M, Bismuth H. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function tests. Transplant. Proc. 27(1), 1142–1143 (1995).
   PubMed Web of Science ®Google Scholar
• Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28(3), 638–645 (1998).
   PubMed Web of Science ®Google Scholar
• Tippner C, Nashan B, Hoshino K et al. Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation 72(6), 1122–1128 (2001).
   PubMed Web of Science ®Google Scholar
• Sun J, Sheil AG, Wang C et al. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes. Transplantation 62(12), 1725–1730 (1996).
   PubMed Web of Science ®Google Scholar
• Wong T, Nouri-Aria KT, Devlin J, Portmann B, Williams R. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 28(2), 443–449 (1998).
   PubMed Web of Science ®Google Scholar
• Abraham SC, Freese DK, Ishitani MB, Krasinskas AM, Wu TT. Significance of central perivenulitis in pediatric liver transplantation. Am. J. Surg. Pathol. 32(10), 1479–1488 (2008).
   PubMed Web of Science ®Google Scholar
• Krasinskas AM, Demetris AJ, Poterucha JJ, Abraham SC. The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers. Liver Transpl. 14(5), 625–632 (2008).
   PubMed Web of Science ®Google Scholar
• Neil DA, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl. Int. 23(10), 971–983 (2010).
   PubMed Web of Science ®Google Scholar
• Uemura T, Ikegami T, Sanchez EQ et al. Late acute rejection after liver transplantation impacts patient survival. Clin. Transplant. 22(3), 316–323 (2008).
   PubMed Web of Science ®Google Scholar
• Lovell MO, Speeg KV, Halff GA, Molina DK, Sharkey FE. Acute hepatic allograft rejection: a comparison of patients with and without centrilobular alterations during first rejection episode. Liver Transpl. 10(3), 369–373 (2004).
   PubMed Web of Science ®Google Scholar
• Hübscher SG. Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl. 14(5), 596–600 (2008).
   PubMed Web of Science ®Google Scholar
• Demirhan B, Bilezikçi B, Haberal AN, Sevmis S, Arat Z, Haberal M. Hepatic parenchymal changes and histologic eosinophilia as predictors of subsequent acute liver allograft rejection. Liver Transpl. 14(2), 214–219 (2008).
   PubMed Web of Science ®Google Scholar
• Gouw AS, van den Heuvel MC, van den Berg AP, Slooff MJ, de Jong KP, Poppema S. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. Transplantation 73(2), 243–247 (2002).
   PubMed Web of Science ®Google Scholar
• Neil DA, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 35(3), 639–651 (2002).
   PubMed Web of Science ®Google Scholar
• Miloh T, Magid MS, Iyer K, Kerkar N, Morotti RA. Chronic rejection preceded by central perivenulitis, rapidly ensuing after liver transplantation in a pediatric patient. Semin. Liver Dis. 29(1), 134–138 (2009).
   PubMed Web of Science ®Google Scholar
• D’Antiga L, Dhawan A, Portmann B et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation 73(1), 80–84 (2002).
   PubMed Web of Science ®Google Scholar
• Hübscher SG. Transplantation pathology. Semin. Liver Dis. 29(1), 74–90 (2009).
   PubMed Web of Science ®Google Scholar
• Lunz JG 3rd, Contrucci S, Ruppert K et al. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am. J. Pathol. 158(4), 1379–1390 (2001).
   PubMed Web of Science ®Google Scholar
• Demetris A, Adams D, Bellamy C et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 31(3), 792–799 (2000).
   PubMedGoogle Scholar
• Nakazawa Y, Jonsson JR, Walker NI et al. Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection. Hepatology 32(6), 1240–1247 (2000).
   PubMed Web of Science ®Google Scholar
• Sebagh M, Rifai K, Féray C et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37(6), 1293–1301 (2003).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Jaffe R, Tzakis A et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am. J. Pathol. 132(3), 489–502 (1988).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Nakamura K, Yagihashi A et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 16(3), 671–681 (1992).
   PubMed Web of Science ®Google Scholar
• Haga H, Egawa H, Shirase T et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl. 10(1), 16–27 (2004).
   PubMed Web of Science ®Google Scholar
• Haga H, Egawa H, Fujimoto Y et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl. 12(3), 457–464 (2006).
   PubMed Web of Science ®Google Scholar
• Hübscher SG. Antibody-mediated rejection in the liver allograft. Curr. Opin. Organ Transplant. 17(3), 280–286 (2012).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Jaffe R, Tzakis A et al. Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers. Transplant. Proc. 21(1 Pt 2), 2217–2220 (1989).
   PubMed Web of Science ®Google Scholar
• Rostron A, Carter V, Mutunga M et al. A case of acute humoral rejection in liver transplantation: successful treatment with plasmapheresis and mycophenolate mofetil. Transpl. Int. 18(11), 1298–1301 (2005).
   PubMed Web of Science ®Google Scholar
• Watson R, Kozlowski T, Nickeleit V et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am. J. Transplant. 6(12), 3022–3029 (2006).
   PubMed Web of Science ®Google Scholar
• Hadaya K, Ferrari-Lacraz S, Giostra E et al. Humoral and cellular rejection after combined liver-kidney transplantation in low immunologic risk recipients. Transpl. Int. 22(2), 242–246 (2009).
   PubMed Web of Science ®Google Scholar
• Wilson CH, Agarwal K, Carter V et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 82(7), 988–989 (2006).
   PubMed Web of Science ®Google Scholar
• Ali S, Ormsby A, Shah V et al. Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. Transpl. Immunol. 26(1), 62–69 (2012).
   PubMed Web of Science ®Google Scholar
• Kozlowski T, Rubinas T, Nickeleit V et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 17(4), 357–368 (2011).
   PubMed Web of Science ®Google Scholar
• Lunz J, Ruppert KM, Cajaiba MM et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am. J. Transplant. 12(1), 171–182 (2012).
   PubMedGoogle Scholar
• Hübscher SG. What is the long-term outcome of the liver allograft? J. Hepatol. 55(3), 702–717 (2011).
   PubMed Web of Science ®Google Scholar
• Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 15(Suppl. 2), S25–S34 (2009).
   PubMed Web of Science ®Google Scholar
• Neuberger J, Portmann B, Macdougall BR, Calne RY, Williams R. Recurrence of primary biliary cirrhosis after liver transplantation. N. Engl. J. Med. 306(1), 1–4 (1982).
   PubMed Web of Science ®Google Scholar
• Knoop M, Bechstein WO, Schrem H, Lobeck H, Hopf U, Neuhaus P. Clinical significance of recurrent primary biliary cirrhosis after liver transplantation. Transpl. Int. 9(Suppl. 1), S115–S119 (1996).
   PubMed Web of Science ®Google Scholar
• Sebagh M, Farges O, Dubel L, Samuel D, Bismuth H, Reynes M. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 65(10), 1328–1333 (1998).
   PubMed Web of Science ®Google Scholar
• Jacob DA, Neumann UP, Bahra M et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin. Transplant. 20(2), 211–220 (2006).
   PubMed Web of Science ®Google Scholar
• Graziadei IW, Wiesner RH, Batts KP et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29(4), 1050–1056 (1999).
   PubMed Web of Science ®Google Scholar
• Alexander J, Lord JD, Yeh MM, Cuevas C, Bakthavatsalam R, Kowdley KV. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 14(2), 245–251 (2008).
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Spiegelman P, Osgood MJ et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 9(7), 727–732 (2003).
   PubMed Web of Science ®Google Scholar
• Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 8(7), 575–581 (2002).
   PubMed Web of Science ®Google Scholar
• Vera A, Moledina S, Gunson B et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360(9349), 1943–1944 (2002).
   PubMed Web of Science ®Google Scholar
• Khettry U, Keaveny A, Goldar-Najafi A et al. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum. Pathol. 34(11), 1127–1136 (2003).
   PubMed Web of Science ®Google Scholar
• Jeyarajah DR, Netto GJ, Lee SP et al. Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: is chronic rejection part of the disease process? Transplantation 66(10), 1300–1306 (1998).
   PubMed Web of Science ®Google Scholar
• Fosby B, Karlsen TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J. Gastroenterol. 18(1), 1–15 (2012).
   PubMed Web of Science ®Google Scholar
• Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl. Int. 21(5), 459–465 (2008).
   PubMed Web of Science ®Google Scholar
• Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 15(3), 330–340 (2009).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Shusang V, Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 14(2), 138–143 (2008).
   PubMed Web of Science ®Google Scholar
• Brandsaeter B, Schrumpf E, Bentdal O et al. Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl. 11(11), 1361–1369 (2005).
   PubMed Web of Science ®Google Scholar
• Grant AJ, Lalor PF, Salmi M, Jalkanen S, Adams DH. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 359(9301), 150–157 (2002).
   PubMed Web of Science ®Google Scholar
• Prados E, Cuervas-Mons V, de la Mata M et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 66(12), 1645–1650 (1998).
   PubMed Web of Science ®Google Scholar
• Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68(2), 253–256 (1999).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Samuel D, Sebagh M et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J. Hepatol. 30(1), 131–141 (1999).
   PubMed Web of Science ®Google Scholar
• Ayata G, Gordon FD, Lewis WD et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 32(2), 185–192 (2000).
   PubMed Web of Science ®Google Scholar
• Duclos-Vallée JC, Sebagh M, Rifai K et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 52(6), 893–897 (2003).
   PubMed Web of Science ®Google Scholar
• Ilyas JA, O’Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract. Res. Clin. Gastroenterol. 25(6), 765–782 (2011).
   PubMed Web of Science ®Google Scholar
• O’Grady JG. Phenotypic expression of recurrent disease after liver transplantation. Am. J. Transplant. 10(5), 1149–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J. Autoimmun. 34(1), 7–14 (2010).
   PubMed Web of Science ®Google Scholar
• González-Koch A, Czaja AJ, Carpenter HA et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl. 7(4), 302–310 (2001).
   PubMed Web of Science ®Google Scholar
• Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral Hepat. 14(Suppl. 1), 89–96 (2007).
   PubMed Web of Science ®Google Scholar
• Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14(Suppl. 2), S27–S35 (2008).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Eghtesad B, Marcos A et al. Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis. Am. J. Surg. Pathol. 28(5), 658–669 (2004).
   PubMed Web of Science ®Google Scholar
• Regev A, Molina E, Moura R et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl. 10(10), 1233–1239 (2004).
   PubMed Web of Science ®Google Scholar
• Petrovic LM. Early recurrence of hepatitis C virus infection after liver transplantation. Liver Transpl. 12(11 Suppl. 2), S32–S37 (2006).
   PubMed Web of Science ®Google Scholar
• Grassi A, Quarneti C, Ravaioli M et al. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 12(11), 1673–1681 (2006).
   PubMed Web of Science ®Google Scholar
• Sadamori H, Yagi T, Iwagaki H et al. Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J. Gastroenterol. Hepatol. 24(4), 574–580 (2009).
   PubMed Web of Science ®Google Scholar
• MacQuillan GC, de Boer WB, Allan JE, Platten MA, Reed WD, Jeffrey GP. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin. Transplant. 24(2), 252–258 (2010).
   PubMed Web of Science ®Google Scholar
• Jain A, Ryan C, Mohanka R et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin. Transplant. 20(5), 624–633 (2006).
   PubMed Web of Science ®Google Scholar
• Schmeding M, Dankof A, Krenn V et al. C4d in acute rejection after liver transplantation – a valuable tool in differential diagnosis to hepatitis C recurrence. Am. J. Transplant. 6(3), 523–530 (2006).
   PubMed Web of Science ®Google Scholar
• Unitt E, Gelson W, Davies SE, Coleman N, Alexander GJ. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl. 15(3), 306–312 (2009).
   PubMed Web of Science ®Google Scholar
• Demetris AJ. Evolution of hepatitis C virus in liver allografts. Liver Transpl. 15(Suppl. 2), S35–S41 (2009).
   PubMed Web of Science ®Google Scholar
• Zekry A, Bishop GA, Bowen DG et al. Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl. 8(3), 292–301 (2002).
   PubMed Web of Science ®Google Scholar
• Dixon LR, Crawford JM. Early histologic changes in fibrosing cholestatic hepatitis C. Liver Transpl. 13(2), 219–226 (2007).
   PubMed Web of Science ®Google Scholar
• Tsamandas AC, Furukawa H, Abu-Elmagd K, Todo S, Demetris AJ, Lee RG. Liver allograft pathology in liver/small bowel or multivisceral recipients. Mod. Pathol. 9(7), 767–773 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrell LD, Wright TL, Roberts J, Ascher N, Lake J. Hepatitis C viral infection in liver transplant recipients. Hepatology 16(4), 865–876 (1992).
   PubMed Web of Science ®Google Scholar
• Bolkhir A, Brunt EM, Solomon HS, Hayashi PH. Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy. Liver Transpl. 13(2), 309–11; author reply 312 (2007).
   PubMed Web of Science ®Google Scholar
• Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 16(11), 1228–1235 (2010).
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 26(2), 459–466 (1997).
   PubMed Web of Science ®Google Scholar
• Fiel MI, Agarwal K, Stanca C et al. Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl. 14(6), 861–871 (2008).
   PubMed Web of Science ®Google Scholar
• Khettry U, Huang WY, Simpson MA et al. Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients. Hum. Pathol. 38(3), 443–452 (2007).
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Samonakis D, Patch D et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 81(3), 488–490 (2006).
   PubMed Web of Science ®Google Scholar
• Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl. 12(5), 827–830 (2006).
   PubMed Web of Science ®Google Scholar
• Berardi S, Lodato F, Gramenzi A et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon α-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 56(2), 237–242 (2007).
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 14(6), 750–755 (2008).
   PubMed Web of Science ®Google Scholar
• Schiano TD, Te HS, Thomas RM, Hussain H, Bond K, Black M. Results of steroid-based therapy for the hepatitis C-autoimmune hepatitis overlap syndrome. Am. J. Gastroenterol. 96(10), 2984–2991 (2001).
   PubMed Web of Science ®Google Scholar
• Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J. Hepatol. 31(Suppl. 1), 210–216 (1999).
   PubMed Web of Science ®Google Scholar
• Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J. Hepatol. 55(1), 207–217 (2011).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436(7053), 967–972 (2005).
   PubMed Web of Science ®Google Scholar
• Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J. Gastroenterol. Hepatol. 23(6), 844–855 (2008).
   PubMed Web of Science ®Google Scholar
• Selzner N, Renner EL, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation 88(10), 1214–1221 (2009).
   PubMed Web of Science ®Google Scholar
• Xirouchakis E, Triantos C, Manousou P et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 15(10), 699–709 (2008).
   PubMed Web of Science ®Google Scholar
• Roche B, Sebagh M, Canfora ML et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 14(12), 1766–1777 (2008).
   PubMed Web of Science ®Google Scholar
• Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl. 10(7), 850–858 (2004).
   PubMed Web of Science ®Google Scholar
• Oton E, Barcena R, Moreno-Planas JM et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am. J. Transplant. 6(10), 2348–2355 (2006).
   PubMed Web of Science ®Google Scholar
• Neff GW, Montalbano M, O’Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-α-2b and ribavirin therapy. Transplantation 78(9), 1303–1307 (2004).
   PubMed Web of Science ®Google Scholar
• Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J. Clin. Invest. 87(6), 1916–1924 (1991).
   PubMed Web of Science ®Google Scholar
• Charco R, Vargas V, Allende H et al. Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection? Transpl. Int. 9(Suppl. 1), S195–S197 (1996).
   PubMedGoogle Scholar
• Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon α-2a and ribavirin. Transplantation 84(2), 180–186 (2007).
   PubMed Web of Science ®Google Scholar
• Carrión JA, Torres F, Crespo G et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 51(1), 23–34 (2010).
   PubMed Web of Science ®Google Scholar
• Carrión JA, Fernández-Varo G, Bruguera M et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 138(1), 147–158.e1 (2010).
   PubMed Web of Science ®Google Scholar
• Rigamonti C, Donato MF, Fraquelli M et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation. Gut 57(6), 821–827 (2008).
   PubMed Web of Science ®Google Scholar
• Kerkar N, Hadzic N, Davies ET et al. De novo autoimmune hepatitis after liver transplantation. Lancet 351(9100), 409–413 (1998).
   PubMed Web of Science ®Google Scholar
• Salcedo M, Vaquero J, Bañares R et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 35(2), 349–356 (2002).
   PubMed Web of Science ®Google Scholar
• Aguilera I, Sousa JM, Gavilán F, Bernardos A, Wichmann I, Nuñez-Roldán A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl. 10(9), 1166–1172 (2004).
   PubMed Web of Science ®Google Scholar
• Avitzur Y, Ngan BY, Lao M, Fecteau A, Ng VL. Prospective evaluation of the prevalence and clinical significance of positive autoantibodies after pediatric liver transplantation. J. Pediatr. Gastroenterol. Nutr. 45(2), 222–227 (2007).
   PubMed Web of Science ®Google Scholar
• Venick RS, McDiarmid SV, Farmer DG et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am. J. Transplant. 7(4), 955–963 (2007).
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Haga H, Egawa H et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation 78(1), 128–135 (2004).
   PubMed Web of Science ®Google Scholar
• Riva S, Sonzogni A, Bravi M et al. Late graft dysfunction and autoantibodies after liver transplantation in children: preliminary results of an Italian experience. Liver Transpl. 12(4), 573–577 (2006).
   PubMed Web of Science ®Google Scholar
• Lohse AW, Obermayer-Straub P, Gerken G et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson’s disease – possible association with a steroid-resistant transplant rejection episode. J. Hepatol. 31(1), 149–155 (1999).
   PubMed Web of Science ®Google Scholar
• Duclos-Vallée JC, Johanet C, Bach JF, Yamamoto AM. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis. J. Hepatol. 33(1), 163–166 (2000).
   PubMed Web of Science ®Google Scholar
• Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nuñez-Roldan A. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant. Proc. 37(9), 3968–3969 (2005).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Mahou M, Salcedo M, Fernandez-Cruz E et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with GSTT1 null genotype as prognostic marker: long-term follow-up after liver transplantation. Transplantation 83(8), 1126–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Salcedo M, Rodríguez-Mahou M, Rodríguez-Sainz C et al. Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl. 15(5), 530–539 (2009).
   PubMed Web of Science ®Google Scholar
• Lohse AW, Weiler-Norman C, Burdelski M. De novo autoimmune hepatitis after liver transplantation. Hepatol. Res. 37(Suppl. 3), S462 (2007).
   PubMed Web of Science ®Google Scholar
• Shaikh OS, Demetris AJ. Idiopathic posttransplantation hepatitis? Liver Transpl. 13(7), 943–946 (2007).
   PubMed Web of Science ®Google Scholar
• Burra P, Mioni D, Cecchetto A et al. Histological features after liver transplantation in alcoholic cirrhotics. J. Hepatol. 34(5), 716–722 (2001).
   PubMed Web of Science ®Google Scholar
• Gelson W, Hoare M, Unitt E et al. Heterogeneous inflammatory changes in liver graft recipients with normal biochemistry. Transplantation 89(6), 739–748 (2010).
   PubMed Web of Science ®Google Scholar
• Ekong UD, Melin-Aldana H, Seshadri R et al. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl. 14(11), 1582–1587 (2008).
   PubMed Web of Science ®Google Scholar
• Evans HM, Kelly DA, McKiernan PJ, Hübscher S. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 43(5), 1109–1117 (2006).
   PubMed Web of Science ®Google Scholar
• Herzog D, Soglio DB, Fournet JC, Martin S, Marleau D, Alvarez F. Interface hepatitis is associated with a high incidence of late graft fibrosis in a group of tightly monitored pediatric orthotopic liver transplantation patients. Liver Transpl. 14(7), 946–955 (2008).
   PubMed Web of Science ®Google Scholar
• Syn WK, Nightingale P, Gunson B, Hubscher SG, Neuberger JM. Natural history of unexplained chronic hepatitis after liver transplantation. Liver Transpl. 13(7), 984–989 (2007).
   PubMed Web of Science ®Google Scholar
• Seyam M, Neuberger JM, Gunson BK, Hübscher SG. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transpl. 13(7), 966–974 (2007).
   PubMed Web of Science ®Google Scholar
• Miyagawa-Hayashino A, Haga H, Egawa H, Hayashino Y, Uemoto S, Manabe T. Idiopathic post-transplantation hepatitis following living donor liver transplantation, and significance of autoantibody titre for outcome. Transpl. Int. 22(3), 303–312 (2009).
   PubMedGoogle Scholar
• Mohamed R, Hubscher SG, Mirza DF, Gunson BK, Mutimer DJ. Posttransplantation chronic hepatitis in fulminant hepatic failure. Hepatology 25(4), 1003–1007 (1997).
   PubMed Web of Science ®Google Scholar
• Haagsma EB, van den Berg AP, Porte RJ et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl. 14(4), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Haagsma EB, Niesters HG, van den Berg AP et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl. 15(10), 1225–1228 (2009).
   PubMed Web of Science ®Google Scholar
• Pischke S, Suneetha PV, Baechlein C et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl. 16(1), 74–82 (2010).
   PubMed Web of Science ®Google Scholar
• Kamar N, Garrouste C, Haagsma EB et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140(5), 1481–1489 (2011).
   PubMed Web of Science ®Google Scholar
• Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 44(1), 7–14 (2006).
   PubMed Web of Science ®Google Scholar
• Colina F, Alberti N, Solis JA, Martinez-Tello FJ. Diffuse nodular regenerative hyperplasia of the liver (DNRH). A clinicopathologic study of 24 cases. Liver 9(5), 253–265 (1989).
   PubMedGoogle Scholar
• Stromeyer FW, Ishak KG. Nodular transformation (nodular “regenerative” hyperplasia) of the liver. A clinicopathologic study of 30 cases. Hum. Pathol. 12(1), 60–71 (1981).
   PubMed Web of Science ®Google Scholar
• Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 20(1 Pt 1), 88–94 (1994).
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Abraham S, Kamath PS. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl. 13(11), 1552–1556 (2007).
   PubMed Web of Science ®Google Scholar
• Mells G, Mann C, Hubscher S, Neuberger J. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl. 15(8), 931–938 (2009).
   PubMed Web of Science ®Google Scholar
• Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 140(1), 51–64 (2011).
   PubMed Web of Science ®Google Scholar
• Adeyi O, Alexander G, Baiocchi L et al.; The Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance (OT). Liver Transpl. doi:10.1002/lt.23481 (2012) (Epub ahead of print).
   Google Scholar
• Louis S, Braudeau C, Giral M et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 81(3), 398–407 (2006).
   PubMed Web of Science ®Google Scholar
• Newell KA, Asare A, Kirk AD et al.; Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest. 120(6), 1836–1847 (2010).
   PubMed Web of Science ®Google Scholar
• Pons JA, Revilla-Nuin B, Baroja-Mazo A et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 86(10), 1370–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao X, Cheng D et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 86(12), 1837–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Bohne F, Martínez-Llordella M, Lozano JJ et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J. Clin. Invest. 122(1), 368–382 (2012).
   PubMed Web of Science ®Google Scholar